Clinical research

Predictors of early and late outcomes after everolimus and paclitaxel-eluting coronary stents

EuroIntervention 2012;7:1030-1042. DOI: 10.4244/EIJV7I9A165

Robert Applegate
Robert J. Applegate1*, MD; James B. Hermiller2, MD; Paul C. Gordon3, MD; Manejeh Yaqub4, MD; Poornima Sood4, MD, M Phil; Xiaolu Su4, MS; Sherry Cao4, MS; Krishnankutty Sudhir4, MD, PhD; Gregg W. Stone5, MD
1. Wake Forest School of Medicine, Winston-Salem, NC, USA; 2. The St. Vincent Heart Center of Indiana, Indianapolis, IN, USA; 3. The Miriam Hospital, Providence, RI, USA; 4. Abbott Vascular, Santa Clara, CA, USA; 5. Columbia University

Aims: To evaluate whether the improved outcomes with newer generation drug-eluting stents (DES) utilising thin-strut stents are consistent among different patient and ang

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

coronarydrug-eluting stentsmacetvfpredictor
Read next article
Clinical long-term outcome after implantation of titanium nitride-oxide coated stents compared with paclitaxel- or sirolimus-eluting stents: propensity-score matched analysis

Latest news